Peripheral and Central Nervous System Drugs Advisory Committee

Peripheral and Central Nervous System Drugs Advisory Committee
Meeting on October 17, 2011, from 8 a.m. to 5 p.m.

Agenda: On October 17, 2011, the committee will discuss supplemental new drug application (sNDA) 21641 (013) for AZILECT (rasagiline mesylate) Tablets, manufactured by Teva Neuroscience, Inc., for the following proposed indication: Treatment of patients with idiopathic (of unknown cause) Parkinson’s disease to slow clinical progression and treat the signs and symptoms of Parkinson’s disease as initial monotherapy (the single drug used to treat) and as adjunct (additional) therapy to levodopa.